{
  "docId": "019de073-4472-76ed-a8f3-3d6ae669b88a",
  "docSlug": "6078678dfcf31020360c86ce90f559c0",
  "documentTitle": "BioNTech | Results Presentation Deck | 32 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 32,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Data shows monovalent BA.1 and bivalent vaccines as 4th doses; includes LOD line and statistical superiority/non-inferiority notes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-4472-76ed-a8f3-3d6ae669b88a/13",
  "deckHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a",
  "deckJsonHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a.json",
  "deckAnchorHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.8,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "chart",
      "text": "FFRNT50 values for OMI 30ug, OMI 60ug, Bivalent 30ug, Bivalent 60ug against BA.1 and BA.4/5",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33cc338e-05b4-4b65-9592-e87f901c4c13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.45,
        "y": 0.3
      },
      "kind": "legend",
      "text": "BA.1 and BA.4/5",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0add4b27-da12-4be7-a7ec-314c2273e2b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Superiority for GMR and non-inferiority for seroresponses (monovalent and bivalent vaccines); “Super” superiority for GMR (monovalent vaccines); Neutralization activity against BA.4/5 reduced",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1aa2ea37-a89c-47bb-a3f1-2b73616e1454",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Internal data. FFRNT, fluorescent foci reduction neutralization test; LOD, limit of detection. GMR, geometric mean ratio. 1 GMR superiority criterion: the lower bound of 95% confidence interval for GMR is >1.0. 2 Non-inferiority criterion: the lower bound of 95% confidence interval for interval for the percentage difference is >-5. 3 GMR “super” superiority criterion: the lower bound of 95% confidence interval for GMR is >1.5",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce58d5ff-f949-479e-8a12-c003201c77e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Omicron-BA.1 Adapted Vaccines as 4th Dose Elicit Improved Omicron Neutralization Response",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da189619-bb1c-465f-8d61-8155cb45ce2e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "caf53cc9-d49f-4125-a4b5-522d3d0ef84c",
      "evidence": "The presentation highlights the risks of not updating vaccines and the benefits of BioNTech's solutions",
      "position": 0,
      "objective": "What are the consequences of not adapting to evolving COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}